3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Entorno inflamatorio diferencial en pacientes con osteoporosis y diabetes mellitus tipo 2 Translated title: Differential inflammatory environment in patients with osteoporosis and type 2 diabetes mellitus

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen Objetivo: La diabetes mellitus tipo 2 (DM2) y la osteoporosis son enfermedades asociadas con un entorno pro-inflamatorio, cuya prevención mediante nuevas estrategias terapéuticas podría evitar su desarrollo. Sin embargo, existe un escaso número de estudios que evalúen el perfil inflamatorio de la osteoporosis en pacientes con DM2. El objetivo de este estudio se centró en evaluar la respuesta inflamatoria inmunitaria mediante concentraciones séricas de nueve citocinas, dos de ellas de carácter antiinflamatorio (IL-10, IL-5) y seis pro-inflamatorias (IL-2, IL-6, IL-12 (p70), IL-17A, TNFα e IFNɣ) en 163 individuos con DM2 y 47 controles. Una subpoblación, formada por 43 pacientes DM2 sin osteoporosis, y 33 con osteoporosis, fue analizada en más profundidad a nivel de parámetros óseos. Además, hemos evaluado las hormonas calciotropas, los marcadores de remodelado óseo, densidad mineral ósea y fracturas vertebrales en la población, y hemos analizado la relación de las citocinas ensayadas con la DM2, la osteoporosis y las fracturas vertebrales prevalentes. Los pacientes con DM2 tenían concentraciones séricas significativamente más altas de IL-10 en comparación con el grupo control (0,5±1 vs. 0,14±0,3 pg/ml; p=0,016) y los niveles de IL-12 p70 se mostraron más bajos en pacientes con DM2 respecto a los controles (2,9±1,6 vs. 3,9±3,1 pg/ml; p=0,027). En el grupo de pacientes con DM2 y osteoporosis, los niveles de la citocina IL-6 resultaron elevados respecto al grupo de DM2 sin osteoporosis (10,9±14,6 vs. 4,5±7,0; p=0,017). También se observó una asociación de IL-5, siendo sus niveles más bajos en el grupo DM2 con osteoporosis (1,7±0,2 vs. 3,8±0,6; p=0,032). Además, la IL-5 mostró una correlación directa con los niveles del biomarcador de formación ósea fosfatasa alcalina ósea (r=0,277, p=0,004) en la subpoblación de pacientes con DM2. El resto de citocinas no mostraron diferencias significativas. Conclusiones: En conclusión, nuestros hallazgos demuestran que en nuestra población de estudio, los pacientes con DM2 respecto a sujetos sanos presentan un perfil inflamatorio opuesto a lo que se espera en situación de hiperglicemia, probablemente como respuesta compensatoria a la inflamación originada. El perfil de citocinas se modifica en la subpoblación de los pacientes diabéticos, dependiendo de la presencia de osteoporosis. En este caso, el perfil inflamatorio en presencia de osteoporosis es coherente con la respuesta esperada.

          Translated abstract

          Summary Objetive: Type 2 diabetes mellitus (DM2) and osteoporosis are diseases associated with a pro-inflammatory environment, the prevention of which through new therapeutic strategies could prevent their development. However, there are few studies that evaluate the inflammatory profile of osteoporosis in patients with DM2. This study focuses on evaluating the inflammatory immune response through serum concentrations of nine cytokines, two of them anti-inflammatory (IL-10, IL-5) and six pro-inflammatory (IL-2, IL-6, IL-12 (p70), IL-17A, TNFα and IFNɣ) in 163 individuals with DM2 and 47 controls. A subpopulation, made up of 43 DM2 patients without osteoporosis, and 33 with osteoporosis, was analyzed in greater depth at the level of bone parameters. Furthermore, we have assessed the calciotropic hormones, bone remodeling markers, bone mineral density and vertebral fractures in the population, and we have analyzed the relationship of the cytokines tested with DM2, osteoporosis and prevalent vertebral fractures. Patients with DM2 had significantly higher serum concentrations of IL-10 compared to the control group (0.5±1 vs. 0.14±0.3 pg/ml; p=0.016) and the levels of IL12 p70 were shown lower in patients with DM2 compared to controls (2.9±1.6 vs. 3.9±3.1 pg/ml; p=0.027). In the group of patients with DM2 and osteoporosis, the levels of the cytokine IL-6 were elevated compared to the group with DM2 without osteoporosis (10.9±14.6 vs. 4.5±7.0; p=0.017). An association of IL-5 was also observed, with its lowest levels in the DM2 group with osteoporosis (1.7±0.2 vs. 3.8±0.6; p=0.032). Furthermore, IL-5 showed a direct correlation with the levels of the bone formation biomarker alkaline bone phosphatase (r=0.277, p=0.004) in the subpopulation of patients with DM2. The rest of cytokines did not show significant differences. ConclusionS: In conclusion, our findings indicate that in our study population, patients with DM2 compared to healthy subjects present an inflammatory profile opposite to what is expected in a hyperglycemic situation, probably as a compensatory response to the inflammation caused. The cytokine profile is modified in the subpopulation of diabetic patients, depending on the presence of osteoporosis. In this case, the inflammatory profile in the presence of osteoporosis is consistent with the expected response.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

          Summary Background One of the global targets for non-communicable diseases is to halt, by 2025, the rise in the age-standardised adult prevalence of diabetes at its 2010 levels. We aimed to estimate worldwide trends in diabetes, how likely it is for countries to achieve the global target, and how changes in prevalence, together with population growth and ageing, are affecting the number of adults with diabetes. Methods We pooled data from population-based studies that had collected data on diabetes through measurement of its biomarkers. We used a Bayesian hierarchical model to estimate trends in diabetes prevalence—defined as fasting plasma glucose of 7·0 mmol/L or higher, or history of diagnosis with diabetes, or use of insulin or oral hypoglycaemic drugs—in 200 countries and territories in 21 regions, by sex and from 1980 to 2014. We also calculated the posterior probability of meeting the global diabetes target if post-2000 trends continue. Findings We used data from 751 studies including 4 372 000 adults from 146 of the 200 countries we make estimates for. Global age-standardised diabetes prevalence increased from 4·3% (95% credible interval 2·4–7·0) in 1980 to 9·0% (7·2–11·1) in 2014 in men, and from 5·0% (2·9–7·9) to 7·9% (6·4–9·7) in women. The number of adults with diabetes in the world increased from 108 million in 1980 to 422 million in 2014 (28·5% due to the rise in prevalence, 39·7% due to population growth and ageing, and 31·8% due to interaction of these two factors). Age-standardised adult diabetes prevalence in 2014 was lowest in northwestern Europe, and highest in Polynesia and Micronesia, at nearly 25%, followed by Melanesia and the Middle East and north Africa. Between 1980 and 2014 there was little change in age-standardised diabetes prevalence in adult women in continental western Europe, although crude prevalence rose because of ageing of the population. By contrast, age-standardised adult prevalence rose by 15 percentage points in men and women in Polynesia and Micronesia. In 2014, American Samoa had the highest national prevalence of diabetes (>30% in both sexes), with age-standardised adult prevalence also higher than 25% in some other islands in Polynesia and Micronesia. If post-2000 trends continue, the probability of meeting the global target of halting the rise in the prevalence of diabetes by 2025 at the 2010 level worldwide is lower than 1% for men and is 1% for women. Only nine countries for men and 29 countries for women, mostly in western Europe, have a 50% or higher probability of meeting the global target. Interpretation Since 1980, age-standardised diabetes prevalence in adults has increased, or at best remained unchanged, in every country. Together with population growth and ageing, this rise has led to a near quadrupling of the number of adults with diabetes worldwide. The burden of diabetes, both in terms of prevalence and number of adults affected, has increased faster in low-income and middle-income countries than in high-income countries. Funding Wellcome Trust.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study.

            The aim of this study was to determine the association between type-2 diabetes mellitus (DM), BMD and fractures in 6,655 men and women aged 55 years and over from the Rotterdam Study. We compared subjects with type-2 DM to subjects without DM. Additionally, subset analyses were performed, dividing subjects on the basis of the glucose tolerance test into already treated DM, newly diagnosed DM, impaired glucose tolerance (IGT) and normal glucose tolerance (NGT, reference). Femoral neck and lumbar spine BMD were measured using DEXA. Nonvertebral fracture ascertainment was performed using an automated record system involving GPs and local hospitals. Although subjects with DM had higher BMD, they had an increased nonvertebral fracture risk: hazard ratio (HR) 1.33 (1.00-1.77). In subset analysis, the increased fracture risk appeared restricted to treated DM subjects only: HR 1.69 (1.16-2.46). Subjects with IGT had a higher BMD, but contrary to treated DM, they had a lower fracture risk: HR 0.80 (0.63-1.00). In conclusion, subjects with type-2 DM and IGT both have a higher BMD. Whereas, subjects with IGT have a decreased fracture risk, subjects with DM (primarily those with already established and treated DM) had an increased fracture risk, probably due to long-term complications associated with DM.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk.

              We studied the association between fractures and type 1 and type 2 diabetes mellitus. In this case-control study, all subjects diagnosed with a fracture (n=124,655) in Denmark served as cases, and for each case three control subjects (n=373,962) matched for sex and age were retrieved from the general population. Type 1 and type 2 diabetes were associated with an increased risk (1) of any fracture (odds ratio [OR]=1.3, 95% CI: 1.2-1.5 for type 1 diabetes and 1.2, 95% CI: 1.1-1.3 for type 2 diabetes after adjustment for confounders) and (2) of hip fractures (OR=1.7, 95% CI: 1.3-2.2 for type 1 diabetes, and 1.4, 95% CI: 1.2-1.6 for type 2 diabetes). Furthermore, type 2 diabetes was associated with a significant increase in forearm fractures (OR=1.2, 95% CI: 1.0-1.5), and type 1 diabetes was associated with an increased risk of spine fractures (OR=2.5, 95% CI: 1.3-4.6), whereas type 2 diabetes was not. Use of metformin and sulphonylureas was associated with a significantly decreased risk of any fracture, whereas a non-significant trend towards decreased risk of any fracture was associated with the use of insulin. Except for a decrease in hip fractures with use of sulphonylureas, no change in fracture risk in the hip, spine or forearm was associated with the use of insulin or oral antidiabetic drugs. Type 1 and type 2 diabetes are associated with an increased risk of any fracture and hip fractures. The use of drugs to control diabetes may reduce the association between diabetes and fractures.
                Bookmark

                Author and article information

                Journal
                romm
                Revista de Osteoporosis y Metabolismo Mineral
                Rev Osteoporos Metab Miner
                Sociedad Española de Investigaciones Óseas y Metabolismo Mineral (Madrid, Madrid, Spain )
                1889-836X
                2173-2345
                March 2022
                : 14
                : 1
                : 34-41
                Affiliations
                [02] Granada orgnameInstituto de Investigación Biosanitaria de Granada (Ibs.GRANADA) orgdiv1Hospital Universitario San Cecilio orgdiv2UGC Endocrinología y Nutrición España
                [08] Granada orgnameHospital Universitario San Cecilio orgdiv1Servicio de Angiología y Cirugía Vascular España
                [07] Granada orgnameInstituto de Investigación Biosanitaria de Granada (Ibs.GRANADA) orgdiv1Hospital Universitario San Cecilio orgdiv2Universidad de Granada España
                [04] orgnameInstituto Biosanitario de Granada orgdiv1Hospital Universitario San Cecilio orgdiv2Unidad de Enfermedades Digestivas España
                [09] Almería orgnameHospital Universitario Torrecárdenas orgdiv1Unidad de Endocrinología y Nutrición España
                [05] Granada orgnameConsejo Superior de Investigaciones Científicas (CSIC) orgdiv1Estación Experimental del Zaidín orgdiv2Departamento de Bioquímica, Biología Celular y Molecular de Plantas España
                [01] Granada Andalucía orgnameUniversidad de Granada orgdiv1Facultad de Medicina orgdiv2Departamento de Medicina Spain
                [10] Granada orgnameInstituto de Investigación Biosanitaria de Granada (Ibs.Granada) orgdiv1Hospital Universitario San Cecilio orgdiv2Servicio de Investigación Proteómica España
                [03] Madrid orgnameInstituto de Salud Carlos III orgdiv1Centro de Investigación Biomédica en Red (CIBER) orgdiv2Área temática CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES) España
                [06] Perth CRAWLEY orgnameUniversidad del Oeste de Australia (UWA) orgdiv1Instituto de Agricultura y Escuela de Agricultura y Medioambiente Australia
                Article
                S1889-836X2022000100004 S1889-836X(22)01400100004
                10.4321/s1889-836x2022000100004
                90578379-8437-4911-bf56-486d0da53ec6

                This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 International License.

                History
                : 08 November 2021
                : 31 December 2019
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 38, Pages: 8
                Product

                SciELO Spain

                Categories
                Originales

                diabetes mellitus tipo 2,osteoporosis,inflamación,citocinas,type 2 diabetes mellitus,cytokines,inflammation

                Comments

                Comment on this article